Navigation Links
French Physicians to Conduct 2000-Patient Study of CATANIA(TM) Coronary Stent
Date:10/30/2009

NEWNAN, Ga., Oct. 30 /PRNewswire/ -- Physicians at more than 40 centers in France have joined a study of the CATANIA(TM) Coronary Stent with NanoThin Polyzene®-F manufactured by CeloNova BioSciences. With Professor Emmanuel Teiger and Doctor Paul Barragan as co-Principal Investigators, the researchers today announced the Assessment of The Latest Non-Thrombogenic Angioplasty (ATLANTA-France) stent study. Each center will enroll 50 patients with the first procedures expected in early November.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081007/CLTU035-b )

(Photo: http://www.newscom.com/cgi-bin/prnh/20081007/CLTU035-a )

The study will evaluate the short-, mid- and long-term safety and efficacy of the CATANIA(TM) coronary stent for the treatment of up to three de novo native coronary artery lesions in a real word setting. "Professor Teiger and Doctor Barragan are independent and respected interventional cardiologists and we look forward to the results of their study," said Thomas A. Gordy, President and Chief Executive Officer of CeloNova BioSciences. "Physicians throughout France have already used the CATANIA(TM) stent, but this registry will increase participation over broad spectrum of new facilities to this stent without drugs on the surface and for which patient do not have to take long-term dual antiplatelet therapy."

The CATANIA(TM) stent is CE Marked and available throughout the European Union, in the Middle East, and Northern Africa. The stent, treated with CeloNova's anti-thrombotic and bacterial resistant Polyzene®-F surface is available in 60 sizes.

About CeloNova BioSciences: Headquartered in Newnan, Georgia, CeloNova develops novel medical devices that are enhanced by one of the Company's proprietary materials, Polyzene®-F, a lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant surface treatment. The Company's current products include Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene®-F. Both products are CE Marked. Embozene(TM) Microspheres have been approved by the FDA for the treatment of hypervascular tumors and arteriovenous malformations. For more information, please visit www.celonova.com

    CONTACT:  Teresa Wilson
              CeloNova BioSciences, Inc.
              +1 (678) 895-6486
              +1 (770) 502-0304
              twilson@celonova.com

SOURCE CeloNova BioSciences, Inc.


'/>"/>
SOURCE CeloNova BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ScienceDirect to Host French-Language Journals from Elsevier Masson
2. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
3. French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees)
4. Pharmaxis Appoints French Distributor for Aridol(TM)
5. Diageo Sponsors Medical Society of the State of New Yorks Physicians Training Program
6. Young Physicians Demanding Advanced Laparoscopic Energy Instruments
7. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
8. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
9. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
10. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
11. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder ... local San Diego Rotary Club. The event entitled “Stem Cells and ... had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: ...
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... instruments and applications consulting for microscopy and surface analysis, Nanoscience Instruments is ... Nanoscience Analytical offers a broad range of contract analysis services for advanced ...
Breaking Biology Technology:
(Date:8/23/2017)... ARMONK, N.Y. , Aug. 23, 2017  The general public,s help ... the human microbiome—the bacteria that live in and on the human body ... ... bacteria in the human microbiome, starting with the gut. The project's goal ... in disease. Photo credit: IBM ...
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
(Date:5/23/2017)... Italy , May 23, 2017  Hunova, the first robotic gym ... trunk, has been officially launched in Genoa, Italy . ... Europe and the USA . The technology ... on the market by the IIT spin-off Movendo Technology thanks to a ... the Multimedia News Release, please click: ...
Breaking Biology News(10 mins):